HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target

HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating on Nektar Therapeutics (NASDAQ: NKTR) and maintained a price target of $185 for the stock.